Nigrostriatal Loop Disruption in Parkinson’s Disease and Striatonigral Degeneration

  • Sadayuki Matsumoto
  • Satoshi Goto
  • Asao Hirano
Part of the Advances in Behavioral Biology book series (ABBI, volume 38A)


Parkinson’s disease (PD) is known to involve degeneration of nigrostriatal dopaminergic neurons, resulting in a dopamine deficiency in the striatum.1 On the other hand, parkinsonism has been described as a clinical manifestation of other extrapyramidal disorders, such as striatonigral degeneration (SND)2 and progressive supranuclear palsy.3 SND was first described as a distinct clinicopathological entity by Adams et al.,2 and symptoms of pure SND are those of PD; while in the SND patients rigidity and slowness of movement of extremities are prominent.2 In addition, it is noteworthy that SND has been suggested to be a true supranigral form of parkinsonism, in which the striatal lesion is supposed to procede the nigral involvement.4


Tyrosine Hydroxylase Substantia Nigra Dopaminergic Neuron Progressive Supranuclear Palsy Lateral Portion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    H. Bernheimer, W. Birkmeyer, O. Hornykiewicz, K. Jellinger, F. Seitelberger, Brain dopamine and the syndromes of Parkinson and Huntington, J. Neurol. Sci. (1974).Google Scholar
  2. 2.
    R. D. Adams, L. van Bogaert, and H. V. Eecken, Striatonigral degeneration, J. neuropathol. Exp. Neurol. 23: 333 (1964).Google Scholar
  3. 3.
    J. C. Steele, J. C. Richardson, and J. Olszewski, Progressive supra-nuclear palsy, Arch. Neurol. 10: 333 (1964).PubMedCrossRefGoogle Scholar
  4. 4.
    A. Borit, L. J. Rubinstein, and H. Urich, The striatonigral degenerations; putaminal pigments and nosology, Brain 98: 101 (1975).PubMedCrossRefGoogle Scholar
  5. 5.
    A. M. Graybiel and C. W. Ragsdale, Biochemical anatomy of the striatum in: “Chemical Neuroanatomy,”P. C. Emson, ed., Raven Press, New York (1983).Google Scholar
  6. 6.
    C. B. Saper and C. K. Petito, Correspondence of melanin-pigmented neurons in human brain with Al-A14 catecholamine cell groups, Brain 105: 87 (1982).PubMedCrossRefGoogle Scholar
  7. 7.
    S. Goto, Y. Matsukado, Y. Mihara, N. Inoue, and E. Miyamoto, Calcineurin in human brain and its relation to extrapyramidal system. Immunohistochemical study on postmortem human brain, Acta Neuropathol. (Berl.) 72: 150 (1986).Google Scholar
  8. 8.
    S. Goto, Y. Matsukado, E. Miyamoto, and M. Yamada, Morphological characterization of the rat striatal neurons expressing calcineurin immunoreactivity, Neuroscience 22: 189 (1987).PubMedCrossRefGoogle Scholar
  9. 9.
    W. J. H. Nauta and V. B. Domesick, Afferent and efferent relationship of the basal ganglia, in: “Function of the Basal Ganglia, Ciba Foundation Symposium 107, ”D. Evered and M. O’Connor, eds., Pitman, London (1984).Google Scholar
  10. 10.
    J. Kish, K. Shannak, and O. Hornykiewicz, Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease, N. Eng. J. Med. 318: 876 (1988).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Sadayuki Matsumoto
    • 1
  • Satoshi Goto
    • 1
  • Asao Hirano
    • 1
  1. 1.Bluestone Laboratory of the Division of Neuropathology Department of Pathology, Montefiore Medical CenterAlbert Einstein College of MedicineBronxUSA

Personalised recommendations